首页> 外文期刊>Applied Microbiology and Biotechnology >Synthetic antibody discovery against native antigens by CRISPR/Cas9-library generation and endoplasmic reticulum screening
【24h】

Synthetic antibody discovery against native antigens by CRISPR/Cas9-library generation and endoplasmic reticulum screening

机译:通过CRISPR / CAS9-库生成和内质网筛选对天然抗原的合成抗体发现

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Despite the significant advances of antibodies as therapeutic agents, there is still much room for improvement concerning the discovery of these macromolecules. Here, we present a new synthetic cell-based strategy that takes advantage of eukaryotic cell biology to produce highly diverse antibody libraries and, simultaneously, link them to a high-throughput selection mechanism, replicating B cell diversification mechanisms. The interference of site-specific recognition by CRISPR/Cas9 with error-prone DNA repair mechanisms was explored for the generation of diversity, in a cell population containing a gene for a light chain antibody fragment. We achieved up to 93% of cells containing a mutated antibody gene after diversification mechanisms, specifically inside one of the antigen-binding sites. This targeted variability strategy was then integrated into an intracellular selection mechanism. By fusing the antibody with a KDEL retention signal, the interaction of antibodies and native membrane antigens occurs inside the endoplasmic reticulum during the process of protein secretion, enabling the detection of high-quality leads for expression and affinity by flow cytometry. We successfully obtained antibody lead candidates against CD3 as proof of concept. In summary, we developed a novel antibody discovery platform against native antigens by endoplasmic synthetic library generation using CRISPR/Cas9, which will contribute to a faster discovery of new biotherapeutic molecules, reducing the time-to-market.
机译:尽管抗体作为治疗剂的显着进展,但仍有很多关于这些大分子的发现的空间。在这里,我们提出了一种新的合成细胞基策略,利用真核细胞生物学来产生高度多样化的抗体文库,同时将它们连接到高通量选择机制,复制B细胞多样化机制。通过CRISPR / CAS9具有易于易于DNA修复机制的现场特异性识别的干扰用于产生多样性,在含有轻链抗体片段的基因的细胞群中。在多样化机制之后,我们在多样化机制后含有高达93%的细胞含有突变的抗体基因,特别是在抗原结合位点之一。然后将该有针对性的变化策略集成到细胞内选择机制中。通过用kdel保持信号融合抗体,在蛋白质分泌过程中,在内质网内发生抗体和天然膜抗原的相互作用,使得通过流式细胞术检测高质量的引线以表达和亲和力。我们成功获得了抗体导致CD3作为概念证明的候选人。总之,我们开发了一种通过CRISPR / CAS9的内质合成文库生成对抗天然抗原的新型抗体发现平台,这将有助于更快地发现新的生物治疗分子,减少上市时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号